The approval was based on data from 2 multinational double-blind, placebo-controlled Phase 3 trials involving 1686 premenopausal women with moderate to severe pain associated with endometriosis.
Elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, was evaluated in two Phase 3 clinical studies in about 1,700 women with moderate-to-severe endometriosis-associated pain.
Embolization for uterine fibroids may be underused in U.S. hospitals, compared with surgery, according to research presented at the annual meeting of the Society of Interventional Radiology, held from March April 4 to 9 in Washington, D.C.
AbbVie has announced positive results from two replicate Phase 3 clinical trials of Elagolix in premenopausal women with endometriosis.
Oophorectomy may lead to increased risk of developing colorectal cancer, according to research reported in the June issue of the British Journal of Surgery.
Laparoscopically confirmed endometriosis is associated with increased subsequent risk of coronary heart disease (CHD), according to a study published online in Circulation: Cardiovascular Quality and Outcomes.
AbbVie and Neurocrine Biosciences announced positive top-line results from the second of two replicate Phase 3 clinical trials of Elagolix in premenopausal women with endometriosis-associated pain.
In 2001 to 2010, 0.5 percent of women experienced ureteric injury in the year after a hysterectomy, with lower rates for benign vs. malignant conditions and rates of injury increasing between 2001 to 2010.
Untreated pelvic pain is common among U.S. women in their childbearing years, according to a study published in Human Reproduction.
Leuprolide, a gonadotropin releasing hormone (GnRH) agonist has been linked to ischemic heart disease and angina in men but a few cases have been reported in women. A case study in Case Reports in Medicine reports on a premenopausal woman with ST elevation myocardial infarction (STEMI) while on leuprolide therapy.
For women with abnormal uterine bleeding and hysteroscopically diagnosed endometrial polyps, outpatient treatment is more cost-effective than inpatient treatment, according to research published in BJOG: An International Journal of Obstetrics and Gynaecology.
Ultrasound is more cost-effective and safer than other imaging technologies for imaging the female pelvis and it should be the first modality used for patients with pelvic symptoms, advocates of the American Institute of Ultrasound in Medicine (AIUM) have proposed.
Menstrual abnormalities, endometriosis, pelvic pain, hysterectomy, and early/surgical menopause are all associated with chronic fatigue syndrome (CFS), according to new research.
AbbVie announced positive results from one of two ongoing Phase 3 trials for elagolix in premenopausal women with endometriosis.
The Food and Drug Administration (FDA) is warning against the use of laparoscopic power morcellators in hysterectomy or myomectomy procedures for the majority of women.
There's no way to guarantee that laparoscopic power morcellation for uterine fibroid removal or hysterectomy won't increase the risk of spreading undetected cancer to other parts of a woman's body, an FDA advisory panel stated.
Morcellator sales have been halted due to concerns that use of the device in fibroid removal may worsen undetected uterine sarcoma.
For pregnant women with abdominal pain or vaginal bleeding, transvaginal sonography is the best modality for diagnosing ectopic pregnancy.
A variant of a gene involved in fatty acid synthesis that is often overproduced in cancers is associated with a higher risk of developing uterine fibroids.
A history of endometriosis increases the risk of developing ovarian cancer, although the increased risk is restricted to specific subtypes of invasive ovarian cancer.